Barclays Begins Coverage on Cooper Companies (NASDAQ:COO)

Research analysts at Barclays started coverage on shares of Cooper Companies (NASDAQ:COO) in a report issued on Monday, Marketbeat.com reports. The firm set an “overweight” rating and a $85.00 price target on the medical device company’s stock. Barclays‘s price target points to a potential upside of 19.37% from the company’s current price.

Other research analysts have also issued reports about the stock. BNP Paribas Exane upgraded shares of Cooper Companies from a “neutral” rating to an “outperform” rating and set a $92.00 price objective on the stock in a research note on Tuesday, July 22nd. Robert W. Baird dropped their price objective on shares of Cooper Companies from $97.00 to $85.00 and set an “outperform” rating on the stock in a research note on Thursday, August 28th. Piper Sandler dropped their price objective on shares of Cooper Companies from $105.00 to $83.00 and set an “overweight” rating on the stock in a research note on Thursday, August 28th. JPMorgan Chase & Co. dropped their price objective on shares of Cooper Companies from $76.00 to $66.00 and set a “neutral” rating on the stock in a research note on Thursday, August 28th. Finally, Wells Fargo & Company dropped their price objective on shares of Cooper Companies from $93.00 to $72.00 and set an “overweight” rating on the stock in a research note on Thursday, August 28th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $84.77.

Cooper Companies Price Performance

Shares of COO opened at $71.21 on Monday. Cooper Companies has a 1-year low of $61.78 and a 1-year high of $109.37. The stock has a market cap of $14.16 billion, a PE ratio of 35.08, a price-to-earnings-growth ratio of 1.82 and a beta of 1.02. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.12 and a quick ratio of 1.24. The firm has a fifty day moving average price of $69.42 and a 200 day moving average price of $73.46.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings data on Wednesday, August 27th. The medical device company reported $1.10 EPS for the quarter, beating analysts’ consensus estimates of $1.07 by $0.03. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 10.08% and a return on equity of 9.82%. Cooper Companies’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.96 earnings per share. Cooper Companies has set its Q4 2025 guidance at 1.100-1.140 EPS. FY 2025 guidance at 4.080-4.120 EPS. As a group, sell-side analysts anticipate that Cooper Companies will post 3.98 EPS for the current year.

Cooper Companies declared that its Board of Directors has initiated a share repurchase program on Wednesday, September 17th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical device company to purchase up to 15.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

Insider Buying and Selling at Cooper Companies

In related news, COO Daniel G. Mcbride bought 3,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were bought at an average cost of $65.04 per share, for a total transaction of $195,120.00. Following the completion of the transaction, the chief operating officer owned 63,120 shares of the company’s stock, valued at $4,105,324.80. This represents a 4.99% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Albert G. White III bought 10,000 shares of the stock in a transaction on Friday, September 5th. The shares were bought at an average price of $68.39 per share, for a total transaction of $683,900.00. Following the completion of the transaction, the chief executive officer directly owned 226,151 shares of the company’s stock, valued at $15,466,466.89. This trade represents a 4.63% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 17,975 shares of company stock valued at $1,216,346. Insiders own 1.98% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in COO. Mitchell & Pahl Private Wealth LLC lifted its holdings in shares of Cooper Companies by 3.8% in the third quarter. Mitchell & Pahl Private Wealth LLC now owns 10,082 shares of the medical device company’s stock valued at $691,000 after purchasing an additional 366 shares in the last quarter. Buckhead Capital Management LLC lifted its holdings in shares of Cooper Companies by 14.3% in the third quarter. Buckhead Capital Management LLC now owns 58,930 shares of the medical device company’s stock valued at $4,040,000 after purchasing an additional 7,368 shares in the last quarter. Czech National Bank lifted its holdings in shares of Cooper Companies by 3.7% in the third quarter. Czech National Bank now owns 50,673 shares of the medical device company’s stock valued at $3,474,000 after purchasing an additional 1,791 shares in the last quarter. Caldwell Trust Co purchased a new stake in shares of Cooper Companies in the second quarter valued at about $274,000. Finally, Orion Porfolio Solutions LLC lifted its holdings in shares of Cooper Companies by 840.5% in the second quarter. Orion Porfolio Solutions LLC now owns 96,592 shares of the medical device company’s stock valued at $6,873,000 after purchasing an additional 86,322 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.